NCT04209712

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

Phase I Clinical Trial of Haploid Donor-derived in Vitro Activated Natural Killer Cells Infusion for Patients With Minimal Residual Disease After Consolidation Therapy for Acute Myeloid Leukemia

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China · Industry
• Sex: All
• Age: 1 Year – 80 Years
• Healthy volunteers: Not accepted

Summary

This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.

Detailed description

Patients of acute myeloid leukemia after chemotherapy with MRD(minimal residual disease) will receive NK cell infusion combined with consolidation chemotherapy. The bone marrow morphology and MRD remission of the patients will be observed 15 days after the same treatment. All patients will be followed up for 1 year. NK cells are prepared in Beijing iCELL Biotechnology Co.,Ltd, which is subsidiary to Shanghai iCELL Biotechnology Co.,Ltd.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	haploid allogeneic NK cell therapy	NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.

Timeline

• Start date: 2020-01-01
• Primary completion: 2020-12-31
• Completion: 2021-12-31
• First posted: 2019-12-24
• Last updated: 2020-07-29

Locations

1 site across 1 country: China